Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.

Congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies (CLOVES) is a sporadically occurring, nonhereditary disorder characterized by asymmetric somatic hypertrophy and anomalies in multiple organs. We hypothesized that CLOVES syndrome would be caused by a somatic mutation arising during early embryonic development. Therefore, we employed massively parallel sequencing to search for somatic mosaic mutations in fresh, frozen, or fixed archival tissue from six affected individuals. We identified mutations in PIK3CA in all six individuals, and mutant allele frequencies ranged from 3% to 30% in affected tissue from multiple embryonic lineages. Interestingly, these same mutations have been identified in cancer cells, in which they increase phosphoinositide-3-kinase activity. We conclude that CLOVES is caused by postzygotic activating mutations in PIK3CA. The application of similar sequencing strategies will probably identify additional genetic causes for sporadically occurring, nonheritable malformations.

[1]  Jamie K Teer,et al.  A mosaic activating mutation in AKT1 associated with the Proteus syndrome. , 2011, The New England journal of medicine.

[2]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[3]  M. Merino,et al.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. , 1991, The New England journal of medicine.

[4]  J. Mulliken,et al.  Complex Spinal-Paraspinal Fast-Flow Lesions in CLOVES Syndrome: Analysis of Clinical and Imaging Findings in 6 Patients , 2011, American Journal of Neuroradiology.

[5]  P. Vogt,et al.  Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Danon,et al.  McCune-Albright Syndrome and Disorders Due to Activating Mutations of GNAS1 , 2007, Journal of pediatric endocrinology & metabolism : JPEM.

[7]  Kylie L. Gorringe,et al.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. , 2012, The Journal of clinical investigation.

[8]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Maria K. Lehtinen,et al.  Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations , 2012, Neuron.

[10]  D. Prabhavathy,et al.  Klippel-trenaunay syndrome , 1994 .

[11]  I. Barroso,et al.  An Activating Mutation of AKT2 and Human Hypoglycemia , 2011, Science.

[12]  D. Gilliland,et al.  Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. , 2010, Blood.

[13]  J. Seidman,et al.  Construction of normalized RNA-seq libraries for next-generation sequencing using the crab duplex-specific nuclease. , 2011, Current protocols in molecular biology.

[14]  S. Egan,et al.  Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. , 2011, Cancer research.

[15]  A. Alomari.  Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome , 2009, Clinical dysmorphology.

[16]  Brian P. Brunk,et al.  Comparative analysis of RNA-Seq alignment algorithms and the RNA-Seq unified mapper (RUM) , 2011, Bioinform..

[17]  J. Mulliken,et al.  PTEN Hamartoma of Soft Tissue: A Distinctive Lesion in PTEN Syndromes , 2012, The American journal of surgical pathology.

[18]  Edward Y Lee,et al.  CLOVES syndrome with thoracic and central phlebectasia: increased risk of pulmonary embolism. , 2010, The Journal of thoracic and cardiovascular surgery.

[19]  A. Alomari.  CLOVE(S) syndrome: Expanding the acronym , 2009, American journal of medical genetics. Part A.

[20]  R. Happle.  Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. , 1987, Journal of the American Academy of Dermatology.

[21]  Linheng Li,et al.  Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. , 2011, Blood.

[22]  J. Seidman,et al.  Loss-of-Function Mutations in PTPN11 Cause Metachondromatosis, but Not Ollier Disease or Maffucci Syndrome , 2011, PLoS genetics.

[23]  Yingwei Chen,et al.  PI3K: A potential therapeutic target for cancer , 2012, Journal of cellular physiology.

[24]  Charis Eng,et al.  A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. , 2011, American journal of human genetics.

[25]  Julie C. Sapp,et al.  Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients , 2007, American journal of medical genetics. Part A.

[26]  S. Durinck,et al.  Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations , 2012, Oncogene.